IP valuation for medical device innovations affected by US policy changes?

Innovative groups including companies of all sizes, universities and individuals seek to maximise the value of their intellectual property by investing in R&D activities and pursuing patent protection. Medical device companies are particularly focused on converting R&D efforts into patent-protected products. However, these companies and innovators face constant challenges resulting from numerous changes in regulations, pricing coverage, tax regimes and IP rights. As a result, corresponding IP values within the medical device industry appear to be declining based on a study of identified licensing transactions and royalty rates. To improve IP value, licensors must focus on demonstrating product and technology value to differentiate their licensing opportunity from others on the market and to command higher royalty rates, better deal terms and potential multiple licensing opportunities across different end markets and licensees.

View the full article from IAM or download here.

Adapt IP proudly announces that Grant Moss and Brian Bochicco were named to Intellectual Asset Management’s (IAM) Leading 300 IP Strategists list.

Adapt IP Ventures, LLC, a patent transaction and advisory company, announced today that members of its team were named to the 2016 edition of IAM Strategy 300 — The World’s Leading IP Strategists. Adapt IP’s Founder & President, Grant Moss and Vice President, Brian Bochicco, were both named in the prestigious list of colleagues serving the IP-related needs of innovative companies. LINK TO ARTICLE